ホーム › 子宮内膜がん › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける子宮内膜がんの臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する23件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- UPMC Cancer Center-Washington, Washington · 23マイル先
- 他1件
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- 他3件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
A Phase 1 Study of the Safety and Tolerability of CTX-10726
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- UPMC Hillman Cancer Center, Pittsburgh
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
被験者募集中第2相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- 他12件
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
被験者募集中第3相
- AHN West Penn Hospital ( Site 6006), Pittsburgh
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Pittsburgh
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
被験者募集中第3相
- Research Site, Pittsburgh
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
被験者募集中第2相
- West Penn Hospital, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
被験者募集中第2相
- 127, Pittsburgh
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
被験者募集中第2相
- West Penn Allegheny Health, Pittsburgh
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
被験者募集中第2相
- West Penn Hospital, Pittsburgh
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
被験者募集中第2相
- Allegheny Health, Pittsburgh
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- Philadelphia, PA28件の研究
- San Antonio, TX27件の研究
- Columbus, OH25件の研究
- Oklahoma City, OK25件の研究
- Chicago, IL25件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 頭頸部扁平上皮癌22件の研究
- 脳卒中22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。